SAM
ITCI

Silphium Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Silphium Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$692K – 59
2024
Q1 		$692K Buy
+10,000
New +$687K 0.35% 43

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silphium Asset Management's ITCI Position: Q2 2024 in Review

Silphium Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 10,000 shares — an estimated $692K sold.

Silphium Asset Management first reported a position in ITCI in Q1 2024 and held it in 1 quarter. The position peaked at $692K in Q1 2024. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Silphium Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Silphium Asset Management sold 10,000 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $692K.
  • Silphium Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 1 quarter.
  • Silphium Asset Management's Intra-Cellular Therapies Inc. position peaked at $692K in Q1 2024.
  • 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Silphium Asset Management's 13F filing for Q2 2024, filed 30 Jan 2025.